GENETICS AND ENVIRONMENTAL FACTORS OF GLAUCOMA & MYOPIA
Professor David Mackey AO,
Professor of Ophthalmology
The Lions Eye Institute,
University of Western Australia
RESEARCHER PROFILE
Filmed in Perth, Western Australia | February 2026
Professor David Mackey, AO is a clinician, scientist and academic. He is Professor of Ophthalmology at UWA and was the Lions Eye Institute’s Managing Director from 2009 until 2018.
A University of Tasmania medical graduate, Professor Mackey completed his ophthalmology training at the Royal Victorian Eye and Ear Hospital in Melbourne. After an MD thesis on Leber Hereditary Optic Neuropathy at the University of Melbourne, he completed fellowships in the US and UK in genetic eye diseases.
A renowned international researcher on the genetics of eye disease, Professor Mackey leads the Lions Eye Institute’s Genetics and Epidemiology research group, which pursues multiple projects aimed at understanding how genes and environment interact to influence an individual’s risk of eye disease.
Professor Mackey collaborates with researchers worldwide. He is a lead investigator in the International Glaucoma Genetics Consortium (IGCC) and the Consortium for Refractive Error and Myopia (CREAM). In the 1990s he coordinated an international consortium across eight countries to establish the frequency of Leber Hereditary Optic Neuropathy (LHON) mutations.
In Australia, he initiated the Glaucoma Inheritance Study in Tasmania – creating one of the largest glaucoma biobanks in the world and contributing to the discovery of more than a dozen genes associated with Mendelian genetic eye disease.
The Twins Eye Study in Tasmania and Brisbane, the Norfolk Island Eye Study, the eye component of the WA Pregnancy (Raine) Cohort, Busselton Healthy Aging Study are his other major projects.
Professor Mackey’s original research, over more than 30 years into the genetics of glaucoma and in the fields of optic atrophy and congenital cataract, has received constant professional accolades, attracted ongoing research funding and led to his publication of more than 400 peer-reviewed papers.
In 2019, he was made an Officer (AO) in the General Division of the Order of Australia for “distinguished service to medicine, and to medical education, in the field of ophthalmology, as a clinician-scientist and academic”.
Source: Lions Eye Institute website
https://orcid.org/0000-0001-7914-4709
-
CASE STUDY Next Generation Condom Contraception
Eudaemon Technologies, an early-stage medtech company with a focus on sexual reproductive health, is developing a hydrogel condom to address the need for a better feeling, next generation condom, with the potential to improve user experience and address issues with traditional latex condoms.
“Over 1 million STI’s being diagnosed every day and up to 120 million unplanned pregnancies every year result in a $60 billion health burden across the globe”, says Co-Founder and Executive Director of Operations, Dr Simon Cook.
Formed in 2018, the company focuses on developing tough hydrogels as an alternative to address issues with odour, colour, and taste commonly associated with latex condoms. This technology can be loaded with small molecule drugs for flavours or anti-STI compounds, and was developed in response to a grant from the Bill and Melinda Gates Foundation to address unplanned pregnancies and STIs.
-
Novel forms of brain stimulation & psychedelic assisted psychotherapy
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD. He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
-
Computer science approach to detecting dementia
Watch Xinyi Wang, a researcher at the Wicking Dementia Research and Education Centre, University of Tasmania talk on identifying new approaches to detecting dementia.
